Live news related to CELLECTIS stock (FR0010425595): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
French biotech company Cellectis saw a significant increase in its stock price, driven by promising clinical trial results and robust trading volumes.
Cellectis, a French biotechnology company, has seen a significant increase in its share price, driven by promising clinical trial results and strong t…
At the annual Congress of the American Society of Hematology, Cellectis presented preliminary data on its eti-cel product, indicating an overall respo…
Cellectis presented preliminary results from the Phase 1 clinical trial of its candidate product eti-cel at the Annual Congress of the American Societ…
Cellectis stock closed on Thursday, December 4 at 4.24 euros, up 5.34% from the previous day. This increase occurs in a context of moderate trading vo…
French biotech company Cellectis experienced a 5.75% decline this Monday, December 1st at the opening, dropping from 4.44 euros the previous day to 4.…
Cellectis announces a webinar on December 4, 2025, to showcase its clinical and strategic advancements.
French biotech Cellectis is down by 4.65% this Wednesday, November 26, trading at 4.31 euros at midday. This technical consolidation comes after a spe…
The stock of French biotech company Cellectis has risen by 12.06% at mid-session this Monday, November 24, trading at 4.60 euros. This surge is part o…
The value of French biotech Cellectis ended Thursday, November 20th session up by 10.12% at 4.30 euros, driven by the announcement of a major technolo…
